Take 2 minutes to complete this short survey to inform the future direction of our education. What is your profession?SelectMedical oncologistClinical oncologistRadiation oncologistSurgeonGeneral practitionerStudentOther: please specifyPlease specify your profession. Select the activities you have engaged with: The importance of shared decision making Patient case study: Assessing recurrence risk in HR+/HER2- early breast cancer Patient case study: Navigating treatment options for HR+/HER2- early breast cancer As a result of participating in the 'The importance of shared decision making' module which measurable changes will you make to your clinical practice? I will integrate all points within the communication aid into my practice I will start the process of shared decision making earlier in the treatment journey I will communicate more in depth about my patients' risk of recurrence I will counsel patients on the outcomes of gene expression tests prior to making a decision on going through with it I will communicate the different treatment options in a more step-by-step manner I will not make a change but it reaffirms my practice I will make a change not listed here: please specify Please specify the change(s) you will make. As a result of participating in the 'Patient case study: Assessing recurrence risk in HR+/HER2- early breast cancer' module, which measurable changes will you make to your clinical practice? I will test for patient- and tumor-related recurrence risk factors as part of diagnostic work-up I will adapt management plans based on both patient-related and tumor-related recurrence risk factors I will incorporare gene expression assays into my routine practice (if available to me) I will not make a change but it reaffirms my practice I will make a change not listed here: please specify Please specify the change(s) you will make. As a result of participating in the 'Patient case study: Navigating treatment options for HR+/HER2- early breast cancer' module, which measurable changes will you make to your clinical practice? I will utilize clinicopathologic variables to inform my first-line treatment decisions for HR+HER2- early breast cancer patients I will use gene expression assays to guide my adjuvant treatment decisions (if available to me) I will incorporate newer therapies, such as PARP inhibitors and CDK4/6 inhibitors, into my clinical practice for patients with a high recurrence risk (if available to me) I will not make a change but it reaffirms my practice I will make a change not listed here: please specify Please specify the change(s) you will make. What topics would you like to see in future educational activities on early breast cancer?EmailThis field is for validation purposes and should be left unchanged. Δ
